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Abstract   
Direct acting antivirals (DAAs) have revolutionised the management of chronic 
hepatitis C virus (HCV) infection. We describe UK real world DAA experience. 
Individuals commencing HCV treatment containing a DAA regimen (Mar 2014 – Nov 
2016), participating in the National HCV Research UK (HCVRUK) Cohort Study were 
recruited from 33 specialist UK HCV centres. Data were prospectively entered at 
sites onto a centralised database. Data are reported as median (Q1-Q3). Of the 1448 
treated patients, 1054 (73%) were males, median age being 54 yrs (47-60), 900 
(62%) being infected with genotype 1 and 455 (31%) genotype 3. The majority, 887 
(61%) had cirrhosis, and 590 (41%) werebeing treatment-experienced. DAA regimens 
utilised: genotype1 sofosbuvir (SOF)/Ledipasvir/+ Ribavirin (RBV) (625/900,69%) and 
Ombitasvir/ Paritaprevir/Dasabuvir/±RBV (220/900, 24%), and in genotype 3 SOF/ 
Daclatasvir +RBV (256/455, 56%) and SOF/pegylated interferon/RBV (157/455, 35%). 
Overall, 1321 (91%) achieved sustained virological response (SVR12), genotype 1 vs. 
3, 93% vs. 87%, p <0.001. Prior treatment, presence of cirrhosis and treatment 
regimen did not impact SVR12. Predictors of treatment failure were genotype 3 
infection, OR 2.015 (95% CI: 1.279-3.176, p=0.003), and male gender, OR 1.878 (95% 
CI: 1.071-3.291, p=0.028). Of those with hepatic decompensation at baseline (n=39), 
51% (n=20) recompensated post treatment, lower baseline serum creatinine being 
associated with recompensation (p=0.029). There were two liver-related deaths, 
both having decompensated disease. This real world UK data, comprising of a 
predominantly cirrhotic HCV genotype 1/3 cohort, confirms DAA efficacy with an 
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overall 91% SVR12, with 51% recompensating post treatment. Genotype 3 infection 
was a predictor of treatment failure. 
Introduction                                                                                                                   
Worldwide, chronic hepatitis C virus (HCV) is a major health burden with 71 million 
infected individuals. (1) There are estimated to be 214,000 people with HCV 
infection in the United Kingdom (UK). (2)                                                                                                                                             
The advent of direct acting antivirals (DAA) has revolutionised the management of 
HCV infection. RegimensThis includes ombitasvir/ paritaprevir/ritonavir+dasabuvir   
OBV/PTVr/DSV) (3), sofosbuvir/ledipasvir (SOF/LDV) (4), sofosbuvir/velpatasvir 
(SOF/VEL) (5), grazoprevir/elbasvir (6) and the recently licensed glecaprevir/ 
pibrentasvir (GLE/PIB) (7) and sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX). (8) 
Sustained virological response (SVR) rates of ~95% can now be achieved in clinical 
trials, even with advanced cirrhosis (3-5,9), prior treatment failures (3,5,8) and 
genotype 3 infection. (7,10) HCV cure is associated with an approximately 70% 
decreased incidence of hepatocellular cancer (HCC) and hepatic decompensation, 
~60% lower risk of cardiovascular events and bacterial infections (11) and reduction 
in overall mortality. (11-12) Benefits are seen even in those with decompensated 
cirrhosis (12-14) though SVR12 rates vary from 82% to 96% (13) with the newer 
regimens (SOF/VEL) (15). 
Most of the safety and efficacy DAA data have been obtained from well-controlled 
and regulated clinical trials. As apparent from the interferon-based studies, SVR 
rates observed in clinical trials do not always mirror those seen in a non-trial setting. 
(16-17) It is imperative therefore to generate real world DAA data to ensure that  
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clinical trial results can be extrapolated to a non-trial setting.                                                                                                                                        
HCV Research UK is a consortium of leading stakeholders in the UK, with a remit to 
address critical gaps in our understanding of the natural history of HCV-related liver 
disease, effectiveness and long-term impact of antiviral treatment and genetic 
factors influencing prognosis. (18) The HCVRUK clinical database and bio bank were 
established in 2012. (18) We have recently published real world data on a  
decompensated cirrhosis HCVRUK cohort treated with DAA (UK Early Access 
Programme [EAP]) (13-14).                                                                                                                           
Here we report on UK real world DAA experience amongst HCVRUK registered 
patients who were treated outside of the EAP.    
Patients and methods                                                                                                                       
Between March 2012 and April 2017, more than 12,000 patients with past or current 
HCV infection (>95%) were enrolled into HCVRUK through attendance at one of 58 
specialist UK HCV clinics.  All adults and children attending a participating clinic and  
willing and able to give informed consent were eligible for inclusion. Exclusion 
criteria were an inability/unwillingness to give informed consent and or being 
incarcerated at the time of the clinic visit. (18)  
The current study comprised recruitment (Mar 2014 – Nov 2016) of patients 
receiving a DAA-containing  regimen other than telaprevir and boceprevir.                                                                                                                       
Individuals participating in the current study were recruited from 33 specialist UK 
HCV centres (see supplementary file for site details). Data were collected through a 
standardised follow up data collection form and included: socio-demographics, 
laboratory data, presence/ absence of cirrhosis, presence of diabetes mellitus, 
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details of hepatic decompensation, liver prognostic scores, viral genotype and viral 
load (VL), HCV treatment history, treatment regimens and outcomes, co morbidity 
and co-medications. Data were prospectively entered at enrolling sites onto a 
centralised database by trained clinical staff.  
Ethical approval for the study was obtained  (NRES Committee East Midlands- Derby 
1,reference no 11/EM/0314), each recruited patient signing an informed consent. 
Those who declined consent were still offered DAA therapy but their data were not 
collected.                                                                                                                        
Patients were assessed at baseline, week 4, week 8, week 12 (end of treatment 
[EOT]) and then week 12 after EOT. SVR12 was defined as the absence of detectable 
virus (at any level) 12 weeks after EOT. Patients whose VL became undetectable at 
any stage during therapy but returned after the EOT were classed as responder-
relapsers. Cirrhosis was defined as one or more of the following:  
- Liver stiffness measurement (LSM) > 12 kPa  
-  APRI score >2 (19) and AST/ALT ratio >1   
- Presence of hepatic decompensation (jaundice [bilirubin > 50 μmol/L, variceal 
bleed, hepatic encephalopathy or ascites) currently or in the past.  
- Imaging suggesting nodular liver with splenomegaly and collaterals 
- A consistent liver biopsy  
Presence or absence of cirrhosis and hepatic decompensation were recorded. 
Reporting severity of ascites and hepatic encephalopathy was not a requirement. 
Hence we only assessed the MELD (20) and UKELD (21) prognostic scores.  
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 There were no standardised criteria for assessment of hepatic recompensation. 
Clinicians recorded if patients were decompensated at time of initiation of DDA 
therapy (yes/no) and then at follow up post HCV treatment (yes/no). Those that 
were decompensated at time of DAA therapy but not during follow up were deemed 
to have recompensated.  
This study was conducted prior to development of national HCV treatment 
guidelines and therefore use of ribavirin was not standardised and was left to the 
discretion of treating Hepatologists. However, those with genotype 3 infection and 
cirrhosis (including prior or current hepatic decompensation) were likely to receive 
ribavirin.  
As this study describes real world treatment outcome data, consistent with other 
real world manuscripts an untreated cohort was not included. 
All data were anonymised under a unique study number prior to analysis. For the 
current study, number of patients with missing data are only specified if it involved > 
5% of the cohort.                                         
Statistical analysis                                                                                                                    
Data are presented as median (Q1-Q3) or number (%) and all reported p values are 
two-tailed. The Mann-Whitney U test was used to compare non-normally distributed 
continuous variables and categorical data were compared using the 2 test. 
Univariate analysis was performed to assess predictors of virological failure. 
Variables with p value <0.10 in univariate analysis were entered into a multivariate 
binary logistic regression model to determine predictors associated with failure to 
achieve SVR12. Data were analysed using SPSS (Chicago, IL, USA) v23.                                                                                                   
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Results                                                                                                                                         
From Mar 2014 – Nov 2016, 1450 patients receiving HCV therapy containing a non 
telaprevir/boceprevir based DAA regimen were registered with HCVRUK. Of these 
two were excluded (unknown genotype and age) with 1448 being eligible for 
inclusion into the study.  Ethnicity data were unavailable in 16/1448 (1%) and of the 
remainder, 1232/1432 (86%) were Caucasian.  Table 1 shows baseline data in the 
whole cohort and stratified by genotype 1 and 3 infection.  
The cohort was predominantly male (n=1054, 73%); median age of 54 yrs (47-60) 
with 13% (n= 183) aged >65yrs of age.  Genotype distribution was as follows: 900 
(62%) genotype 1 (1a 610 (68%), 1b 152 [17%]; in 138 [15%] subtype unknown), 455 
(31%) genotype 3 and 93 (7%) other genotypes (not analysed further). 
Cirrhosis prevalence was 61% (n= 887). The diagnosis of cirrhosis was made as 
follows (some having more than one modality): radiologically, n=687 (77%); LSM > 
12kPa, n= 435 (49%); histologically, n=242 (27%); biochemically, n= 85 (10%); and 
clinically, n= 167 (19%). In 63 (7%), the method for cirrhosis diagnosis washad not 
been specified. Of those with cirrhosis, 12% (n=104) had a history of hepatic 
decompensation, prior to (n=95) or at treatment baseline (n=39).  
Of the treatment experienced patients (n=590 [41%]), 95% had previously failed 
received an interferon-based + telaprevir/boceprevir regimen (table 1).  
Treatment regimens and outcomes in the whole cohort and stratified by genotype 
1 and genotype 3 
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In genotype 1 patients, the predominant regimens were SOF/LDV+RBV (625/900, 
69%) and OBV/PTVr/DSV+RBV (220/900 24%) (table 1). RBV was administrated in 
366/625 (59%) receiving SOF/LDV. This included 81% with and 21% without cirrhosis  
One hundred and ninety out of 220  (86%) on OBV/PTVr/DSV received ribavirin (98% 
with 78% without cirrhosis). Duration of treatment with SOF/LDV+RBV was eight 
weeks in 17% (109/625) and 12 weeks in 73% (454/625. For OBV/PTVr/DSV+RBV, 
74%(162/220) received 12 weeks treatment. Overall, 66% (556/845) of the genotype 
1 cohort received RBV with 73% (616/845) receiving 12 weeks of treatment. 
Therefore additional treatment outcome analysis (with vs. without RBV and < 12 wks 
vs. >12 wks treatment) were not performed. 
 In genotype 3, regimens used were SOF/DAC+RBV (n=256/455, 56%) and 
SOF/Peg/RBV (n=157/455, 35%).  Only five patients (1%), (all on SOF/DAC) did not 
receive ribavirin. For SOF/PEG/RBV and SOF/DAC+RBV, 88% (138/157) and 80% 
(204/256) respectively, received 12 weeks treatment. 
 Fig 1 shows the SVR12 rates in the whole cohort and stratified by genotype 1 and 3, 
SVR12 rates being significantly higher in genotype 1, 93% vs. 87% (p<0.001).  
Baseline data and treatment outcomes in genotype 1a patients stratified by 
presence or absence of cirrhosis and if treatment-naive or treatment-experienced                       
Of the n=610 patients with genotype 1a, n=302 (50%) had cirrhosis and n=229 (38%) 
were treatment-experienced. Overall those without cirrhosis were younger than 
those with cirrhosis (51 [45-57] yrs vs. 55 [50-62] yrs) p<0.001). Comparing non-
cirrhotic treatment-naive versus non-cirrhotic treatment-experienced patients there 
were no significant differences in baseline data (age, platelet count, INR and serum 
Commented [WI1]: I am not sur eof the logic of 
“therefore” further analysis wasn’t performed. Is this 
because the %s receiving RBV and the %s being treated 
for 12 weeks were too high to allow meaningful analysis? 
I would have thought having 34% and 27% in the 
respective minority groups would have been OK for 
further analysis. Perhaps just state categorically 
“Additional treatment analysis …. Etc etc. Or leave the 
sentence out completely. 
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bilirubin, ALT, albumin, sodium and creatinine, [data not shown]), except the non-
cirrhotic treatment-naïve patients had a higher ALT  (55 IU/L [33-94] vs. 40 IU/L [37-
42]), p = 0.029. Similarly comparing genotype 1a patients with cirrhosis treatment-
naive versus cirrhotic treatment-experienced, there were no differences in baseline 
data except the cirrhotic treatment experienced patients were older, (57 yrs [51-63] 
vs. 54 yrs [50-60]), p=0.008.                                                                                                                                         
Fig 2a shows SVR12 rates in genotype 1a patients stratified by absence or presence 
of cirrhosis and if treatment-naive or treatment-experienced. There were no 
statistical differences, SVR12 rates being > 91% in all subgroups (fig 2a) 
Baseline data and treatment outcomes in genotype 1b patients stratified by 
presence and absence of cirrhosis and if treatment-naive or treatment-experienced  
A similar analysis of 152 patients with genotype 1b infection, of whom 81 (53%) had 
cirrhosis and 71 (47%) were treatment-experienced showed that the non-cirrhotic 
patients were younger than the cirrhotic (53 yrs [42-61] vs. 60 yrs [51-67]), p=0.003. 
Comparing baseline data in non-cirrhotic treatment naive with non-cirrhotic 
treatment-experienced patients, the latter were older (59 yrs [47-65] vs. 48 yrs [39-
59]), p=0.038. There were no significant differences in baseline data comparing 
cirrhotic treatment-naive and treatment-experienced patients (data not shown) 
Figure 2b shows SVR12 data in genotype 1b patients stratified by absence and 
presence of cirrhosis and if treatment-naive or treatment-experienced. There were 
no statistical differences with SVR12 rates >93% in all subgroups.                                                        
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There were no differences in overall SVR12 rates in genotype 1a and 1b patients: 
569/610 (93%) vs.144/152 (95%) p=0.512). 
Treatment outcomes in genotype 1 patients stratified by regimen utilised 
In non-cirrhotic and cirrhotic treatment-naive and treatment-experienced patients 
there were no significant differences in SVR12 rates when stratified by treatment 
regimen utilised (SOF/LDV+RBV vs. OBV/PTVr/ DSV +RBV) (Fig 2c and 2d 
respectively)  
Baseline data and treatment outcomes in Genotype 3 patients stratified by 
presence and absence of cirrhosis, if treatment-naive or treatment-experienced 
and by treatment regimen                      
Of the 455 patients with genotype 3 infection, 365 (80%) had cirrhosis, and 181 
(40%) were treatment-experienced. Overall, those without cirrhosis were younger 
than those with cirrhosis (49 yrs [26-78] vs. 53 yrs [25-81]), p = 0.004. In genotype 3 
non-cirrhotics comparing treatment-naive and treatment-experienced patients, 
there were no statistical differences in baseline variables (data not shown). In those 
with cirrhosis, comparing treatment-naive and treatment-experienced patients, 
again there were no differences in baseline variables (data not shown) except the 
latter were significantly older (55 yrs [51-61] vs. 51 yrs [45-57]), p < 0.001).                                                                         
Fig 3a shows SVR12 data in patients with genotype 3 stratified by presence and 
absence of cirrhosis and if treatment-naive or treatment-experienced. Non-cirrhotic 
treatment-naïve patients had numerically higher SVR12 rates compared to cirrhotic 
treatment-experienced (93% vs. 82%, p=0.069) (Fig 3a). 
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Fig 3b shows SVR12 rates in genotype 3 non-cirrhotic patients (treatment-naive and 
treatment-experienced) depending on regimen utilised (SOF/DAC+RBV vs. 
SOF/Peg/RBV). No statistically significant differences in SVR12 rates were observed. 
Fig 4c shows SVR12 rates in genotype 3 cirrhotics (treatment-naive and treatment- 
experienced) depending on treatment regimen. SVR12 rates were numerically higher 
in the treatment-naive group treated with SOF/Peg/RBV compared to SOF/DAC+RBV 
(95% vs. 86%, p=0.054) (Fig 3c).  
Taking genotype 3 as a whole, SVR12 rates were numerically higher with 
SOF/Peg/RBV vs. SOF/DAC+RBV (90% [142/157] vs. 216/256 [84%], p=0.078).  
Factors predicting failure to achieve SVR12  
Of the 127/1448 (9%) who did not achieve SVR12, there were 66 (52%) responder-
relapsers, 10 (8%) non-responders, and the remainder (n=50, 39%) were either lost 
to follow up (n=43) or died (n=7). Treatment relapses were significantly higher in 
genotype 3 vs. genotype 1 (38/455 [8%] vs. 23/900 [3%]), p<0.001.  Table 2 shows 
univariate analysis of demographic and baseline variables in those that failed to 
achieve SVR12. Since 99% with genotype 3 and 86% with genotype 1 treated 
OBV/PTVr/ DSV received ribavirin, the effect of ribavirin on non-SVR12 could only be 
analysed in those receiving SOF/LDV (table 2). Factors predicting non-response on 
univariate analysis were male gender, genotype 3 infection, serum albumin, serum 
bilirubin, platelet count, UKELD score and history of hepatic decompensation prior to 
and at baseline (p < 0.1 for all). Of the 104 with past or current hepatic 
decompensation, 98 (94%) received ribavirin. The UKELD score was a composite of 
other variables and there was collinearity between hepatic decompensation prior to 
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and at baseline. Therefore the following variables with p values <0.1 on univariate 
analysis were entered onto a multivariate binary logistic regression model: male 
gender, genotype 3 infection, serum albumin, serum bilirubin, platelet count and 
hepatic decompensation at baseline. Predictors of failure to achieve SVR 12 were 
genotype 3 infection, OR 2.015 (95% CI: 1.279-3.176, p=0.003) and male gender, OR 
1.878 (95% CI: 1.071-3.291, p=0.028) (table 2b).  
Factors predicting failure to achieve hepatic recompensation post HCV  
treatment  
There were 39/1448 (3%) patients who had hepatic decompensation at baseline 
prior to commencing DAA therapy: ascites (n=21), jaundice (n=6), variceal bleeding 
(n=5), hepatic encephalopathy (HE) (n=2), ascites and jaundice (n=2), ascites and HE 
(n=2), and ascites, jaundice and HE (n=1). Of these, 30 (77%) achieved SVR12, seven 
(18%) being responder-relapsers and two (5%) dying from VB, one during and the 
second after completing treatment. Both had no prior history of variceal bleeding. Of 
the 39 treated patients with hepatic decompensation at baseline, 20 (51%) 
recompensated post treatment (18 achieved SVR12, two responder relapsers). Table 
3 shows baseline data in the cohort with decompensated disease at baseline and 
stratified by those that did and did not achieve recompensation post HCV treatment. 
Those that failed to achieve recompensation post HCV treatment were likely to be 
older (55 yrs vs.53 yrs), male (74% vs. 26%), have lower serum albumin (30 g/L vs. 33 
g/L) and ALT (46 IU/L vs. 68 IU/L) and higher serum creatinine (72 μmol/L vs. 58 
μmol/L). Only the differences in serum creatinine achieved statistical significance 
(p=0.029)(table 3). Due to the small sample size a multiple logistic regression analysis 
was not performed.  
 14 
Three patients (all men, two with genotype 1 and one with genotype 3 infection) had 
de novo hepatic decompensation post DAA therapy.  Two achieved SVR12, one being 
a responder relapser. In addition to the two deaths with variceal bleeding, there 
were five additional deaths: non-liver related in four with cause of death being 
unavailable in one. 
Overall, 63 patients in this real world cohort (4%) had HCC at baseline and nine (<1%) 
patients developed de novo HCC. Detailed HCC data on factors associated with HCC 
development areis being reported separately. 
Discussion 
HCVRUK hasis one of the largest real world HCV clinical databases and bio banks, 
recruiting patients from secondary and tertiary centres across almost all UK 
geographical areas.  Other strengths include data collection in a prospective and 
standardised manner at baseline and longitudinally, inclusion of patients with both 
genotype 1 and 3 and <4% of the cohort being lost to follow up. In contrast other 
real world series have been retrospective (16, 22-27), had a small sample size 
(22,24), or a relatively easy to treat cohort, e.g. genotype 1b (22), or treatment 
naive, non-cirrhotic patients (28-29). Almost two-thirds of our cohort had genotype 
1 infection, higher than that reported nationally (genotype 1, 50.1%, genotype 3, 
38.4%) (30), probably reflecting, until recently, the relatively limited availability of 
genotype 3 treatment options.                                                                                                                                           
The current study focused on a difficult to treat cohort with about two thirds having 
cirrhosis, 41% being treatment-experienced and about a third having genotype 3 
infection. Despite this, overall SVR12 rates were 91%. Predictors of failure to achieve 
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SVR12 were male gender and genotype 3 infection. The significantly lower cure rates 
in genotype 3 patients compared to genotype 1 were due to an almost three fold 
higher relapse rate (8% vs. 3%, p<0.0001) in the former. The 80% prevalence of 
cirrhosis in genotype 3 patients likely contributed to this (31-32) though data on 
resistance-associated variants (RAS) were unavailable. Though lowest SVR12 rates 
(77%) were seen in those with hepatic decompensation at time of antiviral 
treatment, about 50% achieved hepatic recompensation post treatment. 
In our genotype 1 cohort, subtype (1a or 1b), prior treatment history and presence 
of cirrhosis did not impact SVR12: genotype 1a vs. 1b non-cirrhotic treatment-naive 
93% vs. 93%, non-cirrhotic treatment-experienced 91% vs. 93%, cirrhotic treatment- 
naive 94% vs. 97%, and cirrhotic treatment-experienced 95% vs. 95%. Cure rates 
were also independent of the regimen utilised (Fig 2c and 2d).  Our genotype 1 
SVR12 results are consistent with clinical trial data (3-4) and the recent Spanish real 
world cohort (33). In the latter study (16% genotype 1a, ~ 50% cirrhotic/treatment- 
experienced), SVR12 rates with SOF/LDV+RBV vs. OBV/PTVr/DSV +RBV were 97% vs. 
96% respectively with no differences being observed based on subtypes or fibrosis 
stage (33). Similar efficacy in a real world setting with SOF/LDV +RBV vs. 
OBV/PTVr/DSV+RBV have also been reported by other real world series from the 
United States (16,25,29,34). However, unlike Fox (25) and Backus et al (29) we did 
not observe cirrhosis to be associated with lower SVR 12 rates in genotype 1 
patients.                                                                                                               
Until the advent of the newer DAAs (SOF/VEL, GLE/PIB, SOF/VEL/VOX (5, 7-8), 
genotype 3 has traditionally been a more difficult to treat group with cure rates 
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dependant on fibrosis stage, treatment regimens and prior treatment history (31-
32). Our data corroborates this as genotype 3 cirrhotic treatment-experienced 
patients had numerically lower SVR12 rates compared to non-cirrhotic treatment-
naïve patients (82% vs. 93%p =0.069) (Fig 4a). Also overall SVR12 rates were 
numerically higher with SOF/Peg/RBV vs. SOF/DAC±RBV regimens (90% vs. 84%, 
p=0.078). Our overall SVR12 rates with SOF/Peg/RBV (90%) are consistent both with 
real world (American Veterans Association [VA]) (87%) and trial data (ALLY 3+ [88%] 
and the BOSON study). (16,31,32) In the latter study, SVR12 rates reported were: 
non-cirrhotic treatment naive (96%), non-cirrhotic treatment experienced (94%), 
cirrhotic treatment naive (91%) and cirrhotic treatment experienced (86%).(32)  
Interestingly we also observed male gender to be a predictor of non-SVR12 despite 
there being no statistically significant difference in men vs. women as regards 
prevalence of genotype 3 infection (32% vs. 31%), cirrhosis (60% vs. 64%) and prior  
treatment failure (41% vs. 39%), (p>0.290). We do however accept that treatment 
compliance data were unavailable. Since most HCV studies have a male 
preponderance, it is unlikely that the association between gender and  SVR12 can be 
tested in an evenly distributed male vs. female cohort.  
 Older age was not a predictor of treatment failure; 93% of genotype 1 and genotype 
3 patients above the age of 65 yrs achieved SVR12, consistent with real world 
American VA data (SVR12 89.8% vs. 93.8% if aged < 55 yrs vs. 75 yrs respectively). 
(23)                                                                                                                                                                                                                                    
We observed more advanced liver disease as reflected by serum albumin and 
bilirubin, UKELD scores and presence of hepatic decompensation to be associated 
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with non-SVR12 on univariate but not multivariate analysis, most likely due to the 
dominant role played by genotype 3. Our SVR12 rates (77%) in those with hepatic 
decompensation at baseline are consistent with UK EAP (81.6%) (13) and clinical trial 
data (SOLAR 1, SOLAR 2 and ALLY-1) (35-37).  
About 50% of our decompensated cohort recompensated post DAA, all but two 
achieving SVR12. Those likely to benefit were younger, female, have lower serum 
creatinine and better synthetic function. Only serum creatinine achieved statistical 
significance most likely due to multiple testing on a small sample size. Nonetheless 
our results are consistent with the EAP data (13) and the recent study by El-Sherif et 
al (38) confirming that those with more advanced disease are less likely to 
recompensate post DAA therapy. El- Sherif et al found presence of ascites, hepatic 
encephalopathy, serum albumin < 35 g/L or ALT < 60 IU/L and BMI > 25 kg/m2 to be 
associated with an increased risk of not achieving reduction to Child Pugh A disease, 
independent of response to DAA therapy (38). Two (5%) of our decompensated 
patients died during DAA therapy, consistent with clinical trial data (15).     
Though overall only 43/1448 (3%) of the study cohort were lost to follow-up, they 
accounted for 34% of the virological failures (43/127), higher than that reported in 
being consistent with the recent Spanish real world study (9%) (33).  
Our study did have limitations.  This was a predominantly Caucasian cohort and 
hence our results cannot be extrapolated to other ethnic groups. Also, data on DAA 
related adverse events, severity of decompensating events and RAS were not 
available. However, HCVRUK has commenced RAS analysis on all patients failing a 
DAA containing regimen who are undergoing re treatment and this is being reported 
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separately. Finally, our definition of recompensation was not standardised and this 
may have led to bias.   
In conclusion, this real world UK data comprising a well-characterised cohort of 
difficult to treat genotype 1 and genotype 3 HCV patients confirms efficacy of DAA 
with SVR12 rates mirroring clinical trial data. Genotype 3 infection was a predictor of 
not achieving SVR12. Though about 50% of patients with advanced disease 
recompensated post DAA therapy, identifying those with decompensated most likely 
to benefit from antiviral treatment remains challenging.  
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Table 1: Baseline data in whole cohort and stratified by genotype 1 and 3 
 Total cohort             
n= 1448 
Genotype 1               
n= 900 
Genotype 3             
n= 455 
Age (yrs) 54 (47-60) 54 (47-61) 52 (46-59) 
Male 1054 (73%) 656 (73%) 332 (73%) 
BMI (kg/m2) 26.6 (23.5-30.1) 26.2 (23.3-30) 27.2 (23.7-30.7) 
Viral load (IU/ml) Log 6 (5.5-6.6) Log 6 (5.6-6.6) Log 5.8 (5.3-6.5) 
Liver stiffness 
measurement (LSM) kPa  
12 (6.9-21) 9.9 (6.3-16.8) 15.9 (11.9-27.4) 
Platelets (109/L) 161 (107-219) 177 (124-232) 133 (90-176) 
Bilirubin (μmol/L) 11 (8-16) 11 (8-16) 12 (9-18) 
ALT (IU/L) 67 (41-109) 60 (39-96) 80 (49-123) 
Albumin g/L 39 (36-42) 39 (36-42) 39 (35-42) 
INR 1.1 (1-1.2) 1.1 (1-1.1) 1.1 (1-1.2) 
Sodium (mmol/L) 140 (138-141) 140 (138-141) 139 (138-141) 
Creatinine (μmol/L) 70 (61-80) 70 (62-80) 69 (60-79) 
Cirrhosis                              
Prior or baseline 
decompensation  
887 (61%)               
104 (12%) 
465 (52%)                   
45 (10%) 
365 (80%)                
54 (15%) 
MELD score 6 (6-7) 6 (6-7) 6 (6-7) 
UKELD  score 47 (45-49) 46 (45-48) 47 (45-50) 
Treatment-naive  
Treatment-experienced  
858 (59%)                  
590 (41%) 
533 (59%)                   
367 (41%) 
274 (60%)               
181 (40%) 
Prior treatments  
Peg INF+RBV                          
Peg INF+RBV+ 
telapevir/boceprevir       
Standard INF+RBV          
Other regimens* 
 
433 (73%)                 
74 (13%)                    
51 (9%)                       
32 (5%)              
 
235 (64%)                  
74 (20%)                
37 (10%)                        
21 (6%) 
 
161 (89%)             
                                  
11 (6%)                          
9 (5%) 




SOF/PEG/RBV                  
Other regimens                  
 
221 (15%)                           
673 (46%)                          
260  (18%)                         
184 (13%)               
110 (7%) 
 
220 (24%)                
625 (69%)                           




256 (56%)                         
157 (34%)                
42 (9%) 
Overall 879 (61%) had valid LSM. This included 557 with genotype 1 and 276 with genotype 3 had 
valid LSM readings                                                                                                                                                                         
*Other regimens included sofosbuvir (SOF) and simeprevir                                                            
Normal values: platelet, bilirubin 0-21 mol/l, ALT 0-41 iu/L, albumin 35-52g/L, INR 0.8-1.2, sodium,  









Table 2a: Univariate analysis of demographic and baseline variables in those without SVR12  
 Odds Ratio 95% CI                              
upper        lower 
p value  
Male gender 1.581 1.005         2.489  0.048 
Age (yrs)                                       
Age 65 yrs 
0.997                 
0.702 
0.978         1.015         
0.379         1.299 
0.714                      
0.260 
BMI (kg/m2) 1.006 0.966         1.048 0.765 
Viral load (baseline) (IU/L) 1 1                 1 0.92 
Cirrhosis (baseline) 1.213 0.828         1.777 0.322 
Treatment experienced 1.204 0.834         1.737 0.321 
Genotype 1a  





0.428         0.928 
0.263         1.148 




LSM (kPa) 1.013 0.997         1.030 0.124 
Ribavirin non use ** 1.44 0.707         2.936 0.315 
Sodium (mmol/L) 0.969 0.916         1.026  0.285 
Creatinine (μmol/L) 0.995 0.985         1.005  0.324 
Albumin (g/L) 0.930 0.897         0.964  <0.001 
Bilirubin (μmol/L) 1.021 1.009        1.034  0.001 
ALT (IU/L) 1.001 0.999        1.004   0.227 
INR 1.080 0.628        1.859  0.781 
Platelets (109/L) 0.996 0.994        0.999  0.007 
MELD 1.108 0.934        1.314 0.238 
UKELD 1.099 1.031        1.171  0.004 
Hepatic decompensation  
Decompensated at baseline     
Decompensated prior to 
baseline 
 
3.138              
2.192 
 
1.435       6.860        
1.212       3.964 
 
0.004               
0.009 














Table 2b. Multivariate analysis of variables in those without SVR12 




Male gender  0.630 0.286 4.842 1 0.028 1.878 1.071 3.291 
Genotype 3  
(compared to 
genotype 1a) 
0.701 0.232 9.112 1 0.003 2.015 1.279 3.176 
Serum albumin -0.038 0.024 2.498 1 0.114 0.963 0.919 1.009 
Serum bilirubin 0.011 0.008 1.856 1 0.173 1.011 0.995 1.028 
Platelet count 0.000 0.002 0.003 1 0.959 1.000 0.997 1.003 
Baseline hepatic 
decompensation  
























Table 3: Demographic and baseline data in those with hepatic decompensation at baseline and 
stratified by those that did and did not recompensate post HCV treatment  
 Hepatic 
decompensation at 








post HCV  
treatment            
n=19 




















BMI (kg/m2) 26.7 (23.4-32.8) 26.7 (23.4-31.4) 26.9 (20.9-33.2) 1 
Viral load (baseline) 
(IU/ml) 
Log 5.7 (4.9-6.2) Log 5.4 (4.6-5.9) Log 5.99 (5.2-6.5) 0.64 
Treatment 
experienced 
















Sodium (mmol/L) 138 (133-140) 138 (134-139) 139 (132-141) 0.756  
Creatinine (μmol/L) 60 (53-79) 58 (51-66) 72 (59-93) 0.029 
Albumin (g/L) 31 (26-36) 33 (29-36) 30 (26-36)  0.266 
Bilirubin (μmol/L) 32 (17-43) 35 (23-53) 26 (14-42)  0.243 
ALT (IU/L) 49 (38-83) 68 (37-85) 46 (39-79) 0.546 
INR 1.3 (1.2-1.5) 1.4 (1.2-1.6)  1.3 (1.18-1.4)  0.272 
Platelets (109/L) 84 (66-118) 88 (66-120) 84 (57-118) 0.965 
MELD score 7 (6-8) 7 (6-9)  8 (6-8) 0.946 
UKELD score 52 (49-55) 52 (49-56) 52 (46-55) 0.854 
 
  
 
